218 related articles for article (PubMed ID: 14597666)
1. RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development.
Adini I; Rabinovitz I; Sun JF; Prendergast GC; Benjamin LE
Genes Dev; 2003 Nov; 17(21):2721-32. PubMed ID: 14597666
[TBL] [Abstract][Full Text] [Related]
2. Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion, and metastasis.
Jiang K; Sun J; Cheng J; Djeu JY; Wei S; Sebti S
Mol Cell Biol; 2004 Jun; 24(12):5565-76. PubMed ID: 15169915
[TBL] [Abstract][Full Text] [Related]
3. Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects.
Prendergast GC
Curr Opin Cell Biol; 2000 Apr; 12(2):166-73. PubMed ID: 10712917
[TBL] [Abstract][Full Text] [Related]
4. Geranylgeranylated, but not farnesylated, RhoB suppresses Ras transformation of NIH-3T3 cells.
Mazières J; Tillement V; Allal C; Clanet C; Bobin L; Chen Z; Sebti SM; Favre G; Pradines A
Exp Cell Res; 2005 Apr; 304(2):354-64. PubMed ID: 15748883
[TBL] [Abstract][Full Text] [Related]
5. Geranylgeranylated RhoB is sufficient to mediate tissue-specific suppression of Akt kinase activity by farnesyltransferase inhibitors.
Liu A; Prendergast GC
FEBS Lett; 2000 Sep; 481(3):205-8. PubMed ID: 11007964
[TBL] [Abstract][Full Text] [Related]
6. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
DuHadaway JB; Du W; Donover S; Baker J; Liu AX; Sharp DM; Muller AJ; Prendergast GC
Oncogene; 2003 Jun; 22(23):3578-88. PubMed ID: 12789266
[TBL] [Abstract][Full Text] [Related]
7. Cyclin B1 is a critical target of RhoB in the cell suicide program triggered by farnesyl transferase inhibition.
Kamasani U; Huang M; Duhadaway JB; Prochownik EV; Donover PS; Prendergast GC
Cancer Res; 2004 Nov; 64(22):8389-96. PubMed ID: 15548709
[TBL] [Abstract][Full Text] [Related]
8. Genetic response to farnesyltransferase inhibitors: proapoptotic targets of RhoB.
Kamasani U; Liu AX; Prendergast GC
Cancer Biol Ther; 2003; 2(3):273-80. PubMed ID: 12878865
[TBL] [Abstract][Full Text] [Related]
9. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors.
Du W; Prendergast GC
Cancer Res; 1999 Nov; 59(21):5492-6. PubMed ID: 10554025
[TBL] [Abstract][Full Text] [Related]
10. Farnesyltransferase inhibitors disrupt EGF receptor traffic through modulation of the RhoB GTPase.
Wherlock M; Gampel A; Futter C; Mellor H
J Cell Sci; 2004 Jul; 117(Pt 15):3221-31. PubMed ID: 15226397
[TBL] [Abstract][Full Text] [Related]
11. RhoB and the cellular response to farnesyltransferase inhibitors: the search for clues to cell death mechanisms.
Bernhard EJ
Cancer Biol Ther; 2003; 2(3):281-2. PubMed ID: 12878866
[No Abstract] [Full Text] [Related]
12. RhoB differentially controls Akt function in tumor cells and stromal endothelial cells during breast tumorigenesis.
Kazerounian S; Gerald D; Huang M; Chin YR; Udayakumar D; Zheng N; O'Donnell RK; Perruzzi C; Mangiante L; Pourat J; Phung TL; Bravo-Nuevo A; Shechter S; McNamara S; Duhadaway JB; Kocher ON; Brown LF; Toker A; Prendergast GC; Benjamin LE
Cancer Res; 2013 Jan; 73(1):50-61. PubMed ID: 23135917
[TBL] [Abstract][Full Text] [Related]
13. Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter.
Delarue FL; Adnane J; Joshi B; Blaskovich MA; Wang DA; Hawker J; Bizouarn F; Ohkanda J; Zhu K; Hamilton AD; Chellappan S; Sebti SM
Oncogene; 2007 Feb; 26(5):633-40. PubMed ID: 16909123
[TBL] [Abstract][Full Text] [Related]
14. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B.
Montaner S; Sodhi A; Pece S; Mesri EA; Gutkind JS
Cancer Res; 2001 Mar; 61(6):2641-8. PubMed ID: 11289142
[TBL] [Abstract][Full Text] [Related]
15. RhoB facilitates c-Myc turnover by supporting efficient nuclear accumulation of GSK-3.
Huang M; Kamasani U; Prendergast GC
Oncogene; 2006 Mar; 25(9):1281-9. PubMed ID: 16247449
[TBL] [Abstract][Full Text] [Related]
16. Akt is a major angiogenic mediator downstream of the Ang1/Tie2 signaling pathway.
DeBusk LM; Hallahan DE; Lin PC
Exp Cell Res; 2004 Aug; 298(1):167-77. PubMed ID: 15242771
[TBL] [Abstract][Full Text] [Related]
17. Farnesylated RhoB prevents cell cycle arrest and actin cytoskeleton disruption caused by the geranylgeranyltransferase I inhibitor GGTI-298.
Allal C; Pradines A; Hamilton AD; Sebti SM; Favre G
Cell Cycle; 2002; 1(6):430-7. PubMed ID: 12548020
[TBL] [Abstract][Full Text] [Related]
18. Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects.
Prendergast GC; Oliff A
Semin Cancer Biol; 2000 Dec; 10(6):443-52. PubMed ID: 11170866
[TBL] [Abstract][Full Text] [Related]
19. Actin' up: RhoB in cancer and apoptosis.
Prendergast GC
Nat Rev Cancer; 2001 Nov; 1(2):162-8. PubMed ID: 11905808
[TBL] [Abstract][Full Text] [Related]
20. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors.
Liu Ax; Du W; Liu JP; Jessell TM; Prendergast GC
Mol Cell Biol; 2000 Aug; 20(16):6105-13. PubMed ID: 10913192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
